[HTML][HTML] Efficacy and safety of umeclidinium/vilanterol 62.5/25ámcg and tiotropium 18ámcg in chronic obstructive pulmonary disease: Results of a 24-week …
MR Maleki-Yazdi, T Kaelin, N Richard, M Zvarich… - Respiratory …, 2014 - Elsevier
… M. Reza Maleki-Yazdi has acted as a consultant to and received research grants from
Almirall, AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Novartis, …
Almirall, AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Novartis, …
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
D Singh, MR Maleki-Yazdi, L Tombs… - … journal of chronic …, 2016 - Taylor & Francis
Background Minimizing the risk of disease progression and exacerbations is the key goal of
COPD management, as these are well-established indicators of poor COPD prognosis. We …
COPD management, as these are well-established indicators of poor COPD prognosis. We …
[HTML][HTML] Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three …
MR Maleki-Yazdi, D Singh, A Anzueto, L Tombs… - Advances in …, 2016 - Springer
Introduction Dual bronchodilator therapy is reserved as a second-line treatment in patients
with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function …
with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function …
The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada
MR Maleki-Yazdi, SM Kelly, SS Lam, M Marin… - Canadian respiratory …, 2012 - hindawi.com
INTRODUCTION: No recent Canadian studies with physician- and spirometry-confirmed
diagnosis of chronic obstructive pulmonary disease (COPD) that assessed the burden of COPD …
diagnosis of chronic obstructive pulmonary disease (COPD) that assessed the burden of COPD …
Respiratory rate during acute asthma
S Kesten, MR Maleki-Yazdi, BR Sanders, JA Wells… - Chest, 1990 - Elsevier
Asthmatic patients hyperventilate during acute attacks, but controversy persists as to
whether they breathe rapidly, deeply or both. We monitored respiratory rate under the three …
whether they breathe rapidly, deeply or both. We monitored respiratory rate under the three …
[HTML][HTML] Dose determination for a fixed-dose drug combination: a phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD
F Maltais, A Hamilton, F Voß, MR Maleki-Yazdi - Advances in therapy, 2019 - Springer
… M. Reza Maleki-Yazdi acted as a consultant and has received research grants form Almirall,
AstraZeneca, Boehringer Ingelheim, Forrest Laboratories, GlaxoSmithKline, Novartis, Merck…
AstraZeneca, Boehringer Ingelheim, Forrest Laboratories, GlaxoSmithKline, Novartis, Merck…
Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study
MR Maleki-Yazdi, CK Lewczuk… - COPD: Journal of …, 2007 - Taylor & Francis
This pilot study aimed to identify early stages of chronic obstructive pulmonary disease (COPD)
in an urban population of smokers and ex-smokers using the Global Initiative for Chronic …
in an urban population of smokers and ex-smokers using the Global Initiative for Chronic …
[PDF][PDF] Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
R Aalbers, MR Maleki-Yazdi, A Hamilton… - Eur Respir …, 2012 - researchgate.net
• The aim of this study was to determine the optimum once-daily dose of olodaterol (5.0 and
10.0 μg) and tiotropium (1.25, 2.5 and 5.0 μg) in combination when delivered via the …
10.0 μg) and tiotropium (1.25, 2.5 and 5.0 μg) in combination when delivered via the …
Importance of distinguishing between asthma and chronic obstructive pulmonary disease in primary care
…, D Price, P Kardos, MR Maleki-Yazdi - Canadian Family Physician, 2021 - cfp.ca
… Dr M. Reza Maleki-Yazdi has received speaker’s bureau and honoraria and consultancy
fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Nycomed, Novartis, …
fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Nycomed, Novartis, …
[HTML][HTML] Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic …
R Aalbers, MR Maleki-Yazdi, A Hamilton… - Advances in …, 2015 - Springer
Introduction Combining long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists
(LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two …
(LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two …